Healthcare / Medical Care FacilitiesThailand
$8.20
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $209.5M · quality 73.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.1B
P/E
11.4x
↓EV/EBITDA
5.8x
↓ROE
11.3%
↑Gross Margin
27.5%
↓Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-5.7%
FCF CAGR
-1.7%
FCF margin
10.4%
FCF / Net income
0.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.06B · net income $436.2M · FCF $319.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.06B | $3.06B | $2.81B | $2.73B | $3.65B |
| Net Income | $436.2M | $436.2M | $314.4M | $283.9M | $696.6M |
| EBITDA | $734.2M | $734.2M | $578.8M | $539.3M | $1.05B |
| EPS | — | — | 0.53 | 0.50 | 1.22 |
| Gross Margin | 27.5% | 27.5% | 24.8% | 24.6% | 35.2% |
| Operating Margin | 17.8% | 17.8% | 14.1% | 13.2% | 24.2% |
| Net Margin | 14.2% | 14.2% | 11.2% | 10.4% | 19.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.04 | 0.06 |
| Current Ratio | 4.64 | 4.64 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $319.6M | $319.6M | $209.5M | $104.6M | $336.0M |
| Returns | |||||
| ROE | 11.3% | 11.3% | 8.9% | 9.4% | 23.2% |
| Valuation | |||||
| P/E | 11.39 | 11.39 | 15.65 | 15.77 | 7.34 |
| EV/EBITDA | 5.79 | 5.79 | 6.82 | 7.01 | 4.02 |
| P/B | 1.29 | 1.29 | 1.40 | 1.48 | 1.70 |
| Growth & Yield | |||||
| Revenue Growth | 9.0% | 9.0% | 2.8% | -25.0% | — |
| EPS Growth | — | — | 6.6% | -59.2% | — |
| Dividend Yield | 4.5% | 4.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+29.6%
Start / end P/E
n/dx → n/dx
EPS bridge
0.53 → n/d
Residual
+25.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.